Neoadjuvant Treatment of Triple Negative Breast Cancer Patients With Docetaxel and Carboplatin to Assess Anti-tumor Activity
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Triple Negative Breast Neoplasms
Interventions: DRUG: Docetaxel|DRUG: Carboplatin|PROCEDURE: FDG-PET/MR
Sponsor: Washington University School of Medicine
Collaborators: National Institutes of Health (NIH)|National Cancer Institute (NCI)|Breast Cancer Research Foundation|NeoImmune Tech